National Bank of Canada
ACET icon

National Bank of Canada’s Adicet Bio ACET Stock Holding History

National Bank of Canada’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115 Buy
+17
New +$127 ﹤0.01% 2831

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

National Bank of Canada's ACET Position: Q1 2026 in Review

National Bank of Canada opened a new position in Adicet Bio (ACET) in Q1 2026: 17 shares worth $115. The stake represents ﹤0.01% of the portfolio and ranks #2831 among its holdings.

49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • National Bank of Canada held 17 shares of Adicet Bio worth $115 as of Q1 2026.
  • Adicet Bio was a new National Bank of Canada position in Q1 2026.
  • Adicet Bio made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2831 holding.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.